Alendrate

Active ingredient:

Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid;  

Available from:

Viatris Limited

INN (International Name):

Alendronate sodium trihydrate 13.05 mg (Equivalent to 10 mg alendronic acid)

Dosage:

10 mg

Pharmaceutical form:

Tablet

Composition:

Active: Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid   Excipient: Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Povidone

Units in package:

Blister pack, PVC/aluminium, 30 tablets

Class:

Prescription

Prescription type:

Prescription

Manufactured by:

Pharmaceutical Works Polpharma SA

Therapeutic indications:

Alendrate is indicated: · In postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · In postmenopausal women who are at risk of developing osteoporosis Alendrate is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · For the treatment of osteoporosis in men to prevent fractures. · For the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · For treatment of Paget's disease of bone in men and women.

Product summary:

Package - Contents - Shelf Life: Blister pack, PVC/aluminium - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Authorization date:

2004-04-19